FDA Approves New Yaz Label Warnings

In a regulatory letter issued yesterday, the FDA approved the use of new warning labels for Yaz birth control. The new warnings advise consumers of the potential risk of serious blood clots, including deep vein thrombosis, from the use of Yaz.
One study, published in a British medical journal last summer, indicated that women using Yaz have a 6.3 times greater chance of developing blood clots than women using other pills that contain levonorgestrel. Other studies, sponsored by Bayer, Yasmine’s manufacturer, have not found such a correlation.

Continue reading